Just yesterday, there was a news report which suggested that the French government is planning to block the sale of a French generic drug maker and two Indian pharma companies were in fray to buy it. Now it might just appear to be another news, but probably it signals more than it. It is after years of being bogged down by US FDA and other issues of shrinking margins, The move indicates that at least some of them have reached a point where they can again think of inorganic growth to boost growth. There are others who instead of looking for expansion outside India, have been buying products and brands from MNC players. Then there is a third set of companies, which might not look at inorganic acquisition but only look for organic growth and enter new markets and segments. In all conditions, one thing is clear that the condition of the Indian pharma companies is much better than what it was 5 years ago. As the learning of the last decade and debacles get implemented, does it increase the probability of them getting re-rated on a sustained basis?
